STTK (Shattuck Labs, Inc.) Stock Financials & Earnings | Market Cap Arena

STTK (Shattuck Labs, Inc.) Stock Financials & Earnings | Market Cap Arena

STTKShattuck Labs, Inc.

Mkt Cap$291M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$1M

Net Income (TTM)-$55M

EPS (TTM)-$1.02

Free Cash Flow (TTM)-$40M

Gross Margin-86.5%

Op. Margin-5777.8%

Net Margin-5489.5%

FCF Margin-3995.3%

P/S Ratio (TTM)290.8x

P/E Ratio (TTM)—

YoY Rev Growth-84.5%

Employees—

Earnings Reports

Next: Q4 2025 · Mar 26

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q4 22	$390K	-$21M	-$26M
Q1 23	$57K	-$17M	-$22M
Q2 23	$200K	-$18M	-$23M
Q3 23	$686K	-$24M	-$29M
Q4 23	$714K	-$267K	-$19M
Q1 24	$1M	$141K	-$20M
Q2 24	$2M	$647K	-$23M
Q3 24	$3M	$2M	-$18M
Q4 24	$0	$0	-$20M
Q1 25	$0	-$936K	-$14M
Q2 25	$0	-$929K	-$13M
Q3 25	$1M	$1M	-$11M

Valuation

Quarter	P/S	P/E
Q4 22	446.0x	—
Q1 23	410.1x	—
Q2 23	338.5x	—
Q3 23	218.1x	—
Q4 23	175.5x	—
Q1 24	107.1x	—
Q2 24	70.5x	—
Q3 24	45.2x	—
Q4 24	50.8x	—
Q1 25	63.1x	—
Q2 25	97.0x	—
Q3 25	290.8x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$26M	-$27M
Q2 23	-$19M	-$19M
Q3 23	-$17M	-$17M
Q4 23	-$19M	-$19M
Q1 24	-$16M	-$16M
Q2 24	-$11M	-$11M
Q3 24	-$16M	-$16M
Q4 24	-$17M	-$17M
Q1 25	-$12M	-$12M
Q2 25	-$10M	-$10M
Q3 25	-$9M	-$9M
Q4 25	-$8M	-$8M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$75K
Q2 23	$296K
Q3 23	$19K
Q4 23	$17K
Q1 24	$0
Q2 24	$17K
Q3 24	$42K
Q4 24	$0
Q1 25	$0
Q2 25	$0
Q3 25	$71K
Q4 25	$0

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 22	-98.7%	+28.0%
Q1 23	—	-10.1%
Q2 23	+300.0%	-17.2%
Q3 23	+223.6%	+15.1%
Q4 23	+83.1%	-26.3%
Q1 24	+1856.1%	-2.6%
Q2 24	+704.5%	+7.1%
Q3 24	+336.9%	-28.6%
Q4 24	-100.0%	-0.1%
Q1 25	-100.0%	-32.0%
Q2 25	-100.0%	-47.0%
Q3 25	-66.6%	-44.0%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$0	0.0%
Q2 23	$2M	926.0%
Q3 23	$2M	257.1%
Q4 23	$2M	229.7%
Q1 24	$2M	222.0%
Q2 24	$3M	165.6%
Q3 24	$3M	85.3%
Q4 24	$2M	—
Q1 25	$2M	—
Q2 25	$2M	—
Q3 25	$0	0.0%
Q4 25	$2M	—

OpEx Breakdown

Quarter	R&D	G&A
Q4 22	$22M	$3M
Q1 23	$17M	$5M
Q2 23	$18M	$5M
Q3 23	$24M	$5M
Q4 23	$15M	$4M
Q1 24	$16M	$5M
Q2 24	$19M	$5M
Q3 24	$16M	$5M
Q4 24	$15M	$4M
Q1 25	$10M	$4M
Q2 25	$9M	$4M
Q3 25	$8M	$4M

Revenue Segments

Quarter	License
Q3 24	$3M
Q3 25	$1M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$66M	$69M	$135M
Q2 23	$72M	$45M	$117M
Q3 23	$41M	$60M	$101M
Q4 23	$126M	$5M	$131M
Q1 24	$76M	$39M	$115M
Q2 24	$61M	$45M	$105M
Q3 24	$44M	$46M	$90M
Q4 24	$57M	$16M	$73M
Q1 25	$61M	$0	$61M
Q2 25	$50M	$0	$50M
Q3 25	$43M	$0	$43M
Q4 25	$54M	$0	$54M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q4 22	42M	+0.0%
Q1 23	42M	+0.1%
Q2 23	42M	+0.1%
Q3 23	42M	+0.0%
Q4 23	43M	+1.3%
Q1 24	51M	+17.6%
Q2 24	51M	+0.4%
Q3 24	51M	+0.1%
Q4 24	51M	+0.0%
Q1 25	51M	+0.2%
Q2 25	51M	+0.1%
Q3 25	72M	+41.5%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 18	—	—
FY 19	—	—
FY 20	$168K	59
FY 21	$353K	85
FY 22	$6K	105
FY 23	$22K	75
FY 24	$130K	44
FY 25	$5	200K